


GlucoGuard

designed to reduce the serious danger of nocturnal hypoglycemia



Hypoglycemia occurs when blood sugar drops to unsafe levels, which can result in loss of coordination, unconsciousness, and even death.

Hypoglycemia and its complications are compounded during sleep, given the need to wake up the affected patient to treat the condition.

Current continuous glucose monitor devices (CGM) can fail to alert the patient while asleep, leading to extended time in low ranges and drastically increasing the chances of an adverse event occurring.



-1 in 10 Type 1 diabetics will **die** from hypoglycemia

IMD reduces diabetic fatalities from nocturnal hypoglycemia with GlucoGuard, the sole automated glucose delivery device

- Operates with third-party CGM
- Evaluates users' blood glucose levels
- Automatically administers glucose solution
- Prevents adverse events due to hypoglycemia

Target Market

8.4 M

Type 1 diabetic patient can benefit from GlucoGuard globally

\$15.9 B

Global Diabetes Market

\$6.3 B

CGM Continuous Glucose Monitoring Market

*325K devices and subsequent refill subscriptions sold in the first 5 years, assuming a 1% annual market capture

Intellectual Property

Patent files in the oral drug delivery space.

About IMD Solutions, Inc

IMD Solutions, Inc is an patent pending medical device company focused on developing a proprietary automated glucose monitoring and delivery device. GlucoGuard is designed to manage nocturnal hypoglycemia (night time blood sugar lows) for Type 1 diabetics. The company was founded by Zachary Smith while completing his Masters in Biomedical Engineering at ASU. Zach has since teamed up with Bill Colone, who has nearly three decades of serial entrepreneurship in the medical device space, GlucoGuard, Inc. is currently the only provider of an automated glucose delivery system.

The Problem of Nocturnal Hypoglycemia

- Hypoglycemia happens when blood sugar drops to unsafe levels which can result in loss of coordination, unconsciousness, and even death.
- As many as 1 in 10 people living with Type 1 will die from hypoglycemia and its complications.
- While asleep, hypoglycemia and its complications are compounded due the need to wake the affected patient to treat the condition.
- Current continuous blood glucose monitoring devices can fail to alert the patient while asleep, leading to extended time in "low" ranges and drastically increasing the chances of an adverse event.

GlucoGuard's Nocturnal Hypoglycemia Solution

- GlucoGuard is the first and only automated glucose delivery system.
- GlucoGuard operates in conjunction with third-party continuous glucose monitors to evaluate users' blood glucose levels and trends via A.I. algorithms to automatically administer glucose solution as required, preventing hypoglycemic episodes and the adverse events that come with them.

Target Opportunity

- 8.4 Million Type 1 Diabetics Globally, 2 Million Type 1 Diabetics in the U.S.
- Global Type 1 Diabetes market is currently worth 15.95 Billion, predicted to reach 24.3 Billion by 2030 (6.2% CAGR).
- Global Antidiabetics market is currently worth 82.85 Billion, predicted to reach 263 Billion by 2033 (12.25% CAGR).
- Globally, ~6.5 Million type 1 diabetic patients use continuous glucose monitors (CGM).
- Global CGM market is currently worth 6.32 Billion, predicted to reach 13.06 Billion by 2032 (8.4% CAGR).

Management

Zachary Smith, Biomed Engineer
Founder, CEO

Bill Colone, Chemical Engineer
Board Chairman

Partners
ATOM Engineering, Research & Development
UC Irvine AI & App Research

Developer
Dexcom, (Continuous Glucose Monitoring) Registered Developer